Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Share price below 3p, despite the company being in final stages of completing a £100m revolving credit facility. The money needed to complete has been raised, SPV inception costs being paid and this 4m nanocap will have a facility of 100m. For a company valued this low, to get a facility of that size, which is usually the size that FTSE 100 companies complete. Says a lot about the creditors thoughts on the potential and sustainability of this company. A conservative target of £50m.
Currently trading at £4m market cap, a £100m revolving credit facility which is in the final stage pending payment of inception costs of which cash has been raised to fulfil as of two days ago. Therefore it is safe to assume that this deal is ready to be complete coincided by the CEO Gobind stating it would be done within weeks. The facility allows Alpha Growth to purchase policies up to 10 times the value of the original facility, this is a fact that has not yet been grasped by the market as if it was we would not be at 2p but rather in the double digits. The move up to a fair value will happen over the coming days and weeks. Personal target is £50m market cap in the short term.
Currently at £4m market cap, the company are in the final stage of completing a £100m revolving credit facility with a leading UK asset manager. This will allow the company to purchase 100s of million worth of life settlement policies. The balance sheet alone would dwarf the market cap if this was currently at 10p. I have had previous targets of 15m market cap. But feel on completion of this deal, which will inevitably open up the doors to more similar deals will easily send this to a £50m market cap valuation. Completely understand the targets of £1 that the BOD have previously mentioned.
Incredible update by the company. Very pleased with the progress made by the company, will have to re evaluate my targets, exponential growth potential from this current valuation. The revenues from this project alone would dwarf the market cap if this was currently at 10p let alone 2p.
Arguments for:
They have $15m AUM seed investment
4 different investment structures
A board which have worked in life settlments their whole careers and have closed billions $ of these deals.
The business has now been completely operationalised hence the risk that was previously attached has been removed.
The words that it is close is what can be inferred from recents RNS. I stand by my position that this should be 4/5p based on these factors alone. Once these deals are completed and more funds are under managment this will be reach by 16-20m target. Its inevitable. Just patience required.
From its current market cap of only 2.5m this will be a very profitable trade. My target is 20m. These deals are in the final stages of completion as talks have been on going since the last fiscal year as mentioned by the board. If these deals were not close to being completed the board would not have stated that they expect this fiscal year to be very different. We should be trading closer to 4/5p based on the 15m seed investment. A 20m valuation in a niche listed business is easily achievable. There is a good reason as to why the COO has a £100m target they understand the sector and business they are involved in.
Colva is a specialist actuarial services provider and its acquisition will result in the Company having additional in-house experience and knowledge, so reducing its need to engage actuarial consultants. In connection with the acquisition, Rajiv Rebello, who is a Fellow of the Society of Actuaries and previously worked on AIG’s life settlement policy portfolio which had a face value of $18bln, has become the Company’s Chief Actuary and director of Investment Analytics.
At 20m the share price is around 16p. That is my initial target which I believe this will hit fairly easily once the deals are completed. We know from the company that they are working on closing funds immeniently.
Despite this as it stands, the company is still undervalued, this should be around 4/5p, considering the business model, sector, board credentials and 15m AUM seed investment (which suggests they are able to attract money).
As you say Max this has the hallmarks to make investors large returns on investment. GLA
In light of Brexit as you have just mentioned and the resulting economic situation. Funds will be looking to place cash in alternative investmente uncorrelated with the market economy. Alpha Growth and Life settlements ticks the boxes. GLA
Alpha Growth has had some momentum recently, currently priced at 2p at around £3m valuation. Involved in space of life settlements, niche offering for a listed company. Has been listed for nearly two years, that time has been spent on operationalising the business. Well worth taking a look in to the stock. Currently undervalued and potentially huge upside if deals can land which the board are confident of landing.
No need to be 'rampy' the company figures will do the talking. The research simply suggests that at current 2p levels the company is undervalued considering all aspects of the company structure and business. Then deals when they land will take this company to a different level at which point institutions will be the ones showing interest.
SLIM entered the US Life Settlement market in 2003, subsequently providing management or investment advice to global institutional investors across multiple portfolios that have acquired more than 2,800 policies with a face value in excess of $2.9 billion. SLIM has developed expertise in insurance-based investment funds based on UK and US domiciled life policies. These are one of Alpha Growths partners. GLA
Hullfc it has been a long process by the Alpha board to get to this position. They are now in the position to deliver and get down to business, as this is what they have been waiting for. The board themselves are confident as they otherwise would not have stated that they expect this fiscal year to be transformational.